Papakonstantinou N.A.,General Oncology Hospital Agioi Anargyroi |
Baikoussis N.G.,LInstitut Mutualiste Montsuris |
Apostolakis E.,University of Ioannina
Journal of Cardiology | Year: 2014
Coronary endarterectomy is an old surgical procedure against coronary artery disease first described by Baily et al. in 1957. Despite its first adverse results, several current publications have shown that coronary endarterectomy with on-pump or off-pump coronary artery bypass grafting can be safely performed with acceptable mortality, morbidity, and angiographic patency rates. Coronary endarterectomy can assure complete revascularization supplying the myocardium with satisfactory blood flow in cases of a diffusely diseased left anterior descending artery or diffuse calcification, thus preventing residual ischemia. Hence, it is important to evaluate current results, rethink this old recipe, and redefine its indications. © 2014 Japanese College of Cardiology.
Souglakos J.,University of Crete |
Karavasilis V.,Papageorgiou General Hospital |
Tsotra E.,Papageorgiou General Hospital |
Samantas E.,General Oncology Hospital Agioi Anargyroi |
And 11 more authors.
Forum of Clinical Oncology | Year: 2013
Background: Advanced pancreatic adenocarcinoma (APA) remains a difficult to manage disease with a high mortality rate. Limited data is available from the Greek Cancer Registry on patients with pancreatic cancer. Patients & Methods: The PATHOS multicenter survey aimed at capturing real-world data on pancreatic cancer disease status in Greece. A standardized questionnaire administered to ten interviewed physicians specialized in pancreatic cancer, captured data from patient medical records as well as the physicians' opinion about limitations of the most common treatment modalities for APA and the likelihood of using nab-paclitaxel in the metastatic APA population. Results: During 2011, 187 patients with APA, 63.6% of whom had been diagnosed with metastatic (Stage IV) disease, were treated by the participating physicians. Surgery had been performed in 39.7% of patients with locally advanced and in 8.4% of those with metastatic APA. Overall, 62/68 patients with locally advanced disease received chemotherapy (31 adjuvant/neoadjuvant). Of 119 patients with metastatic disease, 101 received chemotherapy (7 adjuvant; 94 palliative). As part of standard practice, 89% of patients with metastatic APA had received firstline therapy, mainly with gemcitabine, gemcitabine +erlotinib or FOLFIRINOX. However, various limitations were reported for gemcitabine +erlotinib and FOLIFIRINOX, underscoring the need for new treatments. Of the physicians, 80% reported that they were highly likely to use the combination of nab-paclitaxel/gemcitabine for metastatic APA in the future. Conclusions: The survey demonstrated that APA in Greece is mostly diagnosed in the metastatic state and underscored the importance of adding new treatment modalities to the current therapeutic armamentarium.
Simou E.,Center for the Prevention of Breast Cancer |
Tsimitselis D.,General Oncology Hospital Agioi Anargyroi |
Tsopanlioti M.,General Oncology Hospital Agioi Anargyroi |
Anastasakis I.,General Oncology Hospital Agioi Anargyroi |
And 4 more authors.
Cancer Epidemiology | Year: 2011
Objective: The aim of the current study was to present early performance indicators of a breast cancer screening program in Greece. Methods: Between March 2004 and July 2009, 9621 women aged between 40 and 69. years were recruited into programme on a voluntary basis. The participating women were residents of two adjacent administrative regions of Greece. Several performance indicators were calculated for the first and subsequent screen, separately. Results: A total of 9621 mammograms were 1st screens and 4462 were subsequent screens. The attendance rate was almost 1.5%. The technical repeat rate was 1.7%. On the 1st screen, the recall rate was 11.4%, while the recall rate of the subsequent screens was 5.5%. The vast majority of detected cancers were invasive and only the 1/7 of cancers was identified as DCIS. As concerns tumour size of invasive cancers, the 1.9% and 16.7% was unknown, in the first and subsequent screen, respectively. Moreover, 38.5% and 44.4% of cancers detected in the 1st and subsequent screen, respectively, were less than 15. mm in diameter. Almost 1/5 of diagnosed cancers were interval cancers. Conclusions: This breast cancer screening programme is the first one in Greece and the attendance rate is extremely low. Taking into account that an organised screening programme may benefit women with a reduction in breast cancer mortality, there is an urgent need to develop a national-based screening programme, to increase participation and to improve the information system used to monitor programme performance. © 2011 Elsevier Ltd.